Skip to main content
Premium Trial:

Request an Annual Quote

Ambry, Kapa Bio Reach Deal on Exome Sequencing Assays

NEW YORK (GenomeWeb) – Ambry Genetics has chosen Kapa Biosystems' Kapa Hyper Prep Kits for Ambry's ExomeNext and ExomeNext-Rapid exome sequencing assays, the companies said this week.

Kapa's kits feature improved library yields, with up to 40 percent of input DNA converted to adapter-ligated library, as well as greater coverage uniformity and a streamlined workflow that requires 35 minutes of hands-on time and less than three hours of total workflow time, Ambry and Kapa said.

The ExomeNext and ExomeNext-Rapid assays are designed specifically for establishing neonatal, pediatric, and adult-onset diagnoses of disease. They sequence and analyze the protein-coding regions in the approximately 20,000 genes in the human genome that code for proteins, and sequence and screen for characterized mutations in the mitochondrial genome. Using Kapa's kits with the assays will allow researchers to discover more actionable mutations more quickly, the companies said.

Financial and other terms of the deal were not disclosed.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.